



# Article Online Crowdfunding for Urologic Cancer Care

Pawel Rajwa <sup>1,2</sup>, Philip Hopen <sup>3</sup>, Jakub Wojnarowicz <sup>2</sup>, Julia Kaletka <sup>2</sup>, Iga Paszkiewicz <sup>2</sup>, Olga Lach-Wojnarowicz <sup>2</sup>, Hadi Mostafaei <sup>1</sup>, Wojciech Krajewski <sup>4</sup>, David D'Andrea <sup>1</sup>, Bartosz Małkiewicz <sup>4</sup>, Andrzej Paradysz <sup>2</sup>, Guillaume Ploussard <sup>5</sup>, Marco Moschini <sup>6</sup>, Benjamin N. Breyer <sup>7,8</sup>, Benjamin Pradere <sup>1,5</sup>, Shahrokh F. Shariat <sup>1,9,10,11,12,13,14</sup> and Michael S. Leapman <sup>15,\*</sup>

- <sup>1</sup> Department of Urology, Medical University of Vienna, 1090 Vienna, Austria
- <sup>2</sup> Department of Urology, Medical University of Silesia, 41-800 Zabrze, Poland
- <sup>3</sup> Data Science & Clinical Analytics, New Century Health, Boston, MA 02481, USA
- <sup>4</sup> Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland
- <sup>5</sup> Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France
- <sup>6</sup> Division of Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
- <sup>7</sup> Department of Urology, University of California San Francisco, San Francisco, CA 94143, USA
- <sup>8</sup> Department of Biostatistics and Epidemiology, University of California San Francisco, San Francisco, CA 94143, USA
- <sup>9</sup> Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia
- <sup>10</sup> Karl Landsteiner Institute of Urology and Andrology, 1090 Vienna, Austria
- <sup>11</sup> Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA
- <sup>12</sup> Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA
- <sup>13</sup> Department of Urology, Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic
- <sup>14</sup> Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman 19328, Jordan
- <sup>15</sup> Department of Urology, Yale University School of Medicine, New Haven, CT 06520, USA
  - Correspondence: michael.leapman@yale.edu; Tel.: +1-203-785-3128

**Simple Summary:** Our goal was to analyze the financial needs of patients with urological cancer on the basis of online crowdfunding campaigns. In our report, we included 2126 individual campaigns fundraising for prostate, bladder, kidney and testicular cancer. We specified the detailed financial needs of uro-oncologic patients, campaigns' characteristics and the factors associated with campaigns' success and high fundraising. Our work showed that, with the constantly increasing costs of medical care, patients are looking for funding from online communities including seeking funds for alternative therapies. Overall, these data point to a wide spectrum of patient needs for urologic cancer care as well as identifiable factors influencing campaign success.

**Abstract:** Background: we aimed to characterize the financial needs expressed through online crowdfunding for urologic cancers. Methods: the data used in this study came from the online crowdfunding platform GoFundMe.com. Using an automated software method, we extracted data for campaigns related to urologic cancers. Subsequently, four independent investigators reviewed all extracted data on prostate, bladder, kidney and testicular cancer. We analyzed campaigns' basic characteristics, goals, fundraising, type of treatment and factors associated with successful campaigns. Results: in total, we identified 2126 individual campaigns, which were related to direct treatment costs (34%), living expenses (17%) or both (48%). Median fundraising amounts were greatest for testicular cancer. Campaigns for both complementary and alternative medicine (CAM) (median \$11,000) or CAM alone (median \$8527) achieved higher fundraising totals compared with those for conventional treatments alone (median \$5362) (p < 0.01). The number of social media shares was independently associated with campaign success and highest quartile of fundraising. Conclusions: using an automated web-based approach, we identified and characterized online crowdfunding for urologic cancer care. These findings indicated a diverse range of patient needs related to urologic care and factors related to campaigns' success.

Keywords: urology; crowdfunding; prostate cancer; bladder cancer; kidney cancer; testicular cancer



Citation: Rajwa, P.; Hopen, P.; Wojnarowicz, J.; Kaletka, J.; Paszkiewicz, I.; Lach-Wojnarowicz, O.; Mostafaei, H.; Krajewski, W.; D'Andrea, D.; Małkiewicz, B.; et al. Online Crowdfunding for Urologic Cancer Care. *Cancers* **2022**, *14*, 4104. https://doi.org/10.3390/ cancers14174104

Academic Editor: Eduardo Bruera

Received: 19 July 2022 Accepted: 23 August 2022 Published: 25 August 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

# 1. Introduction

In recent years, online medical crowdfunding has become an increasingly popular tool to defray the financial toxicity associated with cancer care [1,2]. Present evidence supports a prominent role for crowdfunding in supplementation of cancer care costs and their broader impact on patients, caregivers and communities [1,2]. Initially adopted in countries without universal healthcare coverage, such as the United States, online crowdfunding has expanded worldwide and enable patients to raise funds for cancer therapies and indirect treatment-related expenses [3,4].

Urologic malignancies, including prostate, bladder, kidney and testicular cancer constitute approximately 16.5% of all cancer diagnoses and are responsible for 10.8% of all cancer-related deaths [5]. A wide variety of therapeutic options are appropriate for urologic cancers, including surveillance, radical or organ-sparing surgeries, chemo, radiation, immunotherapy, as well as investigational or experimental approaches. Therefore, the spectrum of personal and financial hardships associated with their diagnosis may vary by cancer type and manner of treatment [6,7]. Due to growing interests in complementary and alternative medicine (CAM), the true scale of financial burdens associated with urologic cancer remains incompletely defined [1,2]. Furthermore, while it is apparent that cancer diagnosis has a direct impact on physical and mental health, the financial toxicity of cancer care cannot be underestimated [8–10]. The increased risk of bankruptcy, loss of work-related income, and un- and underinsurance may delay or even prevent care-seeking of needy cancer patients, leading to higher morbidity and mortality [7,8]. Thus, many urologic cancer rations and their families seek assistance for financial needs during cancer treatment through a variety of means.

Up until now, there has been only sparse data analyzing online medical crowdfunding in urologic oncology [11,12]. Hence, through large-scale analysis of online crowdfunding campaigns, we aimed to focus on crowdfunding for urologic cancer care and related expenses. Our objective was to characterize online crowdfunding campaigns for urologic cancer and to evaluate financial needs, campaign characteristics, goals and factors associated with success.

## 2. Materials and Methods

This study was based on data from GoFundMe.com, the largest online crowdfunding platform. We performed data extraction using an automated web browser (Selenium, https: //www.selenium.dev/) to identify English-language campaigns for common urologic cancers (prostate, bladder, kidney, and testicular) and extracted the hyperlink address. Next, we exported text from each campaign using a web-based tool (scrapy.org) [4]. Four independent investigators (J.W., J.K., O.P., O.L.W.) subsequently performed a manual search to exclude campaigns fundraising for charities, animals, events, research, and other cancers and analyzed the campaigns' descriptions to determine direct needs and patient characteristics. We categorized complementary and alternative medicine (CAM) as described previously [2]. Disagreements were resolved at the authors' consensus meeting. Next, within a three-day period, we reevaluated ongoing campaigns to exclude deactivated ones and updated the figures to mitigate the time differences of manual analysis.


Association between campaigns' characteristics and cancer types or type of treatments were assessed using the Pearson's Chi-squared test, Fisher's exact test or Kruskal–Wallis rank sum test, as appropriate [13,14]. Univariable and multivariable logistic regression analyses were to performed to evaluate factors associated with successful campaigns (defined as reaching  $\geq$ 100% of the fundraising goal) and highest fundraisers (a highest quartile dollar amount). We used Firth correction to mitigate the bias associated with the disbalance between dependent variable groups [15]. Models' discrimination was tested with the area under the curve (AUC) derived from the receiver operating (ROC) curve. Analyses were performed using R Version 4.2 (R Foundation for Statistical Computing, Vienna, Austria, 2022).

# 3 of 11

# 3. Results

The final study cohort included 2126 (67.88% of initially extracted) eligible campaigns (Table 1, Figure 1). The total requested amount was \$46,369,821, and \$19,879,097 was collected during a median of 920 (IQR 573–1336) days since the campaign was initiated. Most campaigns originated from the US (95%). The primary needs expressed by campaigns were direct treatment costs (34%), living expenses (e.g., transportation, lost wages, nonmedical bills) (17%) or both (48%). The median fundraised totals differed by cancer type: testicular cancer \$6005 (IQR 3285–11,090), kidney cancer \$5810 (IQR 2628–13,272), prostate cancer \$5233 (IQR 2171–12,255) and bladder cancer \$4062 (IQR 2284–8570) (p < 0.01). Campaigns for testicular cancer more frequently reached their stated fundraising goal (23%), had the highest median number of social media shares (median 546 [IQR 320–976]), and had the most donors (median 72 [IQR 43–125]), but the lowest amount collected per donor (median \$83 [IQR 66–109]) (all p < 0.01).





Overall Cancer Type p-Value Characteristic Kidney, Bladder, Prostate, Testicular. N = 2126 N = 568 (27%) N = 579 (27%) N = 372 (17%) N = 607 (29%) 2016 (95%) 527 (93%) 557 (96%) 362 (97%) 570 (94%) 0.005 Campaigns from US 10,000 10,000 12,525 10,727 10,000 Goal amount (\$) 0.004 (5000 - 25,000)(5000-20,000) (7500 - 25,000)(5000 - 25,000)(5500 - 20,000)5208 5810 5233 6005 Amout collected (\$) 4062 (2284-8570) < 0.001 (2565-11,315) (2628-13,272) (2171-12,255) (3285-11,090) % Goal collected 0.50 (0.24-0.84) 0.41 (0.19-0.73) 0.51 (0.24-0.83) 0.44 (0.19-0.80) 0.60 (0.33-0.95) < 0.001 Sucessfull campain 363 (17%) 73 (13%) 92 (16%) 57 (15%) 141 (23%) < 0.001 (goal reached) 920 (573-1336) 926 (589-1342) 835 (553-1271) 1018 (619-1384) 0.001 Campaign days running 870 (556-1302) Amount collected per < 0.001 6 (3-12) 5 (2-9) 6 (3-15) 6 (2-14) 6 (3-12) day (\$) < 0.001 Donors No. 57 (31-111) 42 (24-80) 63 (34-137) 49 (22-106) 72 (43-125) Amount collected per 91 (69-122) 98 (73-127) 92 (69-120) 100 (69-139) 83 (66-109) < 0.001 donor (\$) 421 (208-781) 284 (152-554) < 0.001 Shares No. 482 (246-863) 370 (137-686) 546 (320-976) Amount collected per 13 (7-26) 13 (7-27) < 0.001 14 (8-27) 16 (9-30) 12 (7-21) share (\$) < 0.001 Followers No. 60 (32-115) 43 (26-84) 64 (36-138) 51 (23-109) 76 (46-127) Updates No. 0.3 2(0-5)2(0-5)2(0-7)2(0-5)2(0-6)Description length 248 (159-392) 234 (148-360) 249 (160-418) 254 (156-427) 255 (168-382) 0.051 (words) Female 360 (17%) 165 (29%) 195 (34%) 0 (0%) 0 (0%) < 0.001 Histology provided 379 (18%) 94 (17%) 165 (28%) 30 (8.1%) 90 (15%) < 0.001 47 (8.3%) 63 (11%) 74 (12%) 0.002 First-person description 245 (12%) 61 (16%) **Religious** references 878 (41%) 220 (39%) 258 (45%) 163 (44%) 237 (39%) 0.10 Children mentions 972 (46%) 310 (55%) 264 (46%) 206 (55%) 192 (32%) < 0.001 Relationship status 930 (44%) 274 (48%) 213 (37%) 177 (48%) 266 (44%) < 0.001 provided Job status provided 985 (46%) 274 (48%) 253 (44%) 130 (35%) 328 (54%) < 0.001 < 0.001 Family status provided 1602 (75%) 385 (68%) 487 (84%) 258 (69%) 472 (78%) 1.00 (1.00-3.00) 1.00 (1.00-3.00) 1.00 (1.00-3.00) 2.00 (1.00-4.00) 1.00 (1.00-2.00) < 0.001 Photos No. Family photo provided 1071 (50%) 281 (49%) 287 (50%) 189 (51%) 314 (52%) 0.8 Un-/underinsurance 0.001 623 (29%) 180 (32%) 165 (28%) 131 (35%) 147 (24%) mentions Fundraising for 703 (34%) 140 (25%) 219 (41%) 134 (36%) 210 (36%) < 0.001 treatment Fundraising for treatment & living 985 (48%) 290 (52%) 251 (47%) 169 (46%) 275 (47%) 0.13 expenses Fundraising only for 358 (17%) 124 (22%) 67 (12%) 68 (18%) 99 (17%) < 0.001 living expenses No data/Not applicable 80 Fundrising for 79 (5.6%) 22 (6.1%) 3 (0.8%) 52 (22%) 2 (0.4%) < 0.001 alternative treatment Fundraising for < 0.001 312 (87%) 356 (94%) 435 (97%) 1256 (89%) 153 (65%) conventional treatment Fundraising for < 0.001 conventional & 83 (5.9%) 25 (7.0%) 19 (5.0%) 29 (12%) 10 (2.2%) alternative treatment

**Table 1.** Characteristics of 2126 GoFundMe.com online crowdfunding campaigns fundraising for urologic malignancies stratified by cancer type.

Characteristic	Overall	Cancer Type						
	N = 2126	Bladder, N = 568 (27%)	Kidney, N = 579 (27%)	Prostate, N = 372 (17%)	Testicular, N = 607 (29%)	<i>p</i> -Value		
No data/Not applicable	708							
Localized disease	183 (14%)	57 (20%)	72 (19%)	27 (12%)	27 (6.1%)	< 0.001		
Nonlocalized disease	1147 (86%)	232 (80%)	306 (81%)	192 (88%)	417 (94%)	< 0.001		
No data on cancer advancement	796							
Fundraising for surgery	977 (58%)	260 (60%)	293 (62%)	86 (28%)	338 (70%)	< 0.001		
Fundraising for chemotherapy	851 (50%)	234 (54%)	161 (34%)	79 (26%)	377 (78%)	<0.001		
Fundraising for radiation therapy	254 (15%)	53 (12%)	87 (19%)	80 (26%)	34 (7.0%)	< 0.001		
Fundraising for immunotherapy	109 (6.5%)	49 (11%)	49 (10%)	8 (2.6%)	3 (0.6%)	<0.001		
n (%); Median (IQR)								

Table 1. Cont.

Abbreviations: IQR, interquartile range; n, number.

We further compared fundraising for campaigns directed at CAM alone (5.6%), both CAM and conventional treatments (5.9%), and conventional treatments only (89%) (Table 2, Figure 2) [2]. Campaigns for CAM, alone or in combination, were more common in prostate cancer (22% and 12%, respectively), and more frequently originated in countries outside of the US (13% vs. 4%; p = 0.003). Campaigns for CAM, alone or in combination with conventional treatments, had higher fundraising goals compared to those for conventional treatment (median: \$25,000 [IQR 15,750-40,000] vs. \$25,000 [IQR 12,500-50,000] vs. \$10,000 [IQR 7000–25,000], respectively; p < 0.001) and had higher fundraising totals (\$8527 [IQR 4762-16,206] vs. \$11,000 [IQR 4830-20,702] vs. \$5362 [IQR 2708-11,334], respectively; p < 0.001). CAM-directed campaigns had a higher number of social media shares compared with conventional therapy alone (median 456 [IQR 177–712] vs. 584 [IQR 292–938) vs. 431 [IQR 236–806]; *p* = 0.017), a higher amount collected per donor (\$124 [IQR 99–195] vs. \$111 [IQR 86–156] vs. \$91 [IQR 69–119]; *p* = 0.006) and per social media share (\$23 [IQR 13–35] vs. \$19 [IQR 9–32] vs. \$13 [IQR 7–24]; *p* < 0.001) for CAM-alone, CAM and conventional therapy and conventional therapy alone, respectively. There were no differences in terms of disease advancement (nonlocalized: 87% vs. 94% vs. 84%; p = 0.09). Campaigns fundraising for alternative/conventional treatment were more often started outside the US (13% vs. 4%; p = 0.003).


**Table 2.** Characteristics of 1418 GoFundMe.com online crowdfunding campaigns fundraising for urologic malignancies stratified by treatment type.

	Overall					
Characteristic	N = 1418	Alternative, N = 79 (5.6%)	both, N = 83 (5.9%)	Conventional, N = 1256 (89%)	<i>p</i> -Value	
Cancer Type					< 0.001	
Bladder	359 (25%)	22 (28%)	25 (30%)	312 (25%)		
Kidney	378 (27%)	3 (3.8%)	19 (23%)	356 (28%)		
Prostate	234 (17%)	52 (66%)	29 (35%)	153 (12%)		
Testicular	447 (32%)	2 (2.5%)	10 (12%)	435 (35%)		
Campaigns from US	1351 (95%)	76 (96%)	72 (87%)	1203 (96%)	0.003	
Goal amount (\$)	12,500 (7500–25,000)	25,000 (15,750–40,000)	25,000 (12,500–50,000)	10,000 (7000–25,000)	< 0.001	

Table 2. Cont.

	Overall		Treatment Type				
Characteristic	N = 1418	Alternative, N = 79 (5.6%)	both, N = 83 (5.9%)	Conventional, N = 1256 (89%)	<i>p</i> -Value		
Amount collected (\$)	5732 (2845–12,102)	8527 (4762–16,206)	11,000 (4830–20,702)	5362 (2708–11,334)	< 0.001		
% Goal collected	48 (23–83)	41 (17–72)	41 (19–75)	49 (24–84)	0.038		
Successful campain (goal reached)	231 (16%)	6 (7.6%)	9 (11%)	216 (17%)	0.031		
Campaing days running	944 (581–1348)	1049 (685–1378)	1025 (670–1306)	928 (571–1348)	0.3		
Amount collected per day (\$)	6 (3–13)	9 (6–18)	10 (5–25)	6 (3–12)	< 0.001		
Donors No.	61 (33–115)	76 (38–124)	89 (50–143)	59 (32–113)	0.006		
Amount collected per donor (\$)	93 (70–125)	124 (99–195)	111 (86–156)	91 (69–119)	<0.001		
Shares No.	443 (236–813)	456 (177–712)	584 (292–938)	431 (236–806)	0.017		
Amount collected per share (\$)	13 (7–26)	23 (13–35)	19 (9–32)	13 (7–24)	< 0.001		
Followers No.	63 (35–117)	76 (39–118)	86 (51–146)	61 (34–116)	0.023		
Updates No.	2.0 (1.0-6.0)	3.0 (1.0-6.5)	2.0 (1.0-6.5)	2.0 (1.0-6.0)	0.2		
Description lenght	276 (180–424)	317 (223–584)	359 (208–534)	268 (178–413)	< 0.001		
Female	238 (17%)	7 (8.9%)	14 (17%)	217 (17%)	0.2		
Histology provided	288 (20%)	9 (11%)	15 (18%)	264 (21%)	0.10		
First-person description	180 (13%)	17 (22%)	19 (23%)	144 (11%)	< 0.001		
Religious references	597 (42%)	38 (48%)	38 (46%)	521 (41%)	0.4		
Children mentions	613 (43%)	36 (46%)	50 (60%)	527 (42%)	0.005		
Relationship status provided	611 (43%)	38 (48%)	44 (53%)	529 (42%)	0.10		
Job status provided	665 (47%)	30 (38%)	28 (34%)	607 (48%)	0.009		
Family status provided	1050 (74%)	49 (62%)	69 (83%)	932 (74%)	0.009		
Photos No.	1 (1–3)	2.00 (1-5)	2 (1–4)	1 (1–3)	0.004		
Family photo provided	695 (49%)	35 (44%)	46 (55%)	614 (49%)	0.4		
Un-/uninsurance mention	500 (35%)	42 (53%)	42 (51%)	416 (33%)	< 0.001		
Fundraising only for treatment	591 (42%)	50 (63%)	44 (53%)	497 (40%)	< 0.001		
Fundraising for treatment and living expenses	827 (58%)	29 (37%)	39 (47%)	759 (60%)	< 0.001		
Localized disease	144 (15%)	7 (13%)	4 (6.2%)	133 (16%)	0.089		
Nonlocalized disease	802 (85%)	47 (87%)	61 (94%)	694 (84%)	0.089		
Fundraising for surgery	977 (69%)	0 (0%)	42 (51%)	935 (74%)	< 0.001		
Fundraising for chemotherapy	851 (60%)	0 (0%)	40 (48%)	811 (65%)	< 0.001		
Fundraising for radiation therapy	254 (18%)	0 (0%)	17 (20%)	237 (19%)	<0.001		
Fundraising for immunotherapy	109 (7.7%)	0 (0%)	17 (20%)	92 (7.3%)	< 0.001		
n (%); Median (IQR)							

Abbreviations: IQR, interquartile range; n, number.



**Figure 2.** Selected figures of 1418 GoFundMe.com online crowdfunding campaigns fundraising for urologic malignancies stratified by treatment type.

In multivariable analysis, social media shares (odds ratio [OR] per 100 shares: 1.03, 95% confidence interval [CI] 1.01–1.05, p < 0.001) and campaigns for testicular cancer (OR 2.03, 95% CI 1.34–3.11, p < 0.001) were associated with completion of fundraising goals (Table 3). Factors associated with high fundraising campaigns (1st quartile; >\$11,300) included social media shares (OR per 100 shares 1.13, 95% CI, 1.10–1.16, p < 0.001), initial description length (OR per 100 words 1.08, 95% CI 1.02–1.14, p = 0.004), collecting for CAM alone (OR 2.56, 95% CI 1.33–4.99, p = 0.005), CAM and conventional treatment (OR 2.15, 95% CI 1.22–3.79, p = 0.009), and nonlocalized disease (OR 2.37, 95% CI 1.38–4.06, p = 0.001).

**Table 3.** Uni- and multivariable logistic regression analyses for campaigns reaching goal amount (successful campaign) and highest fundraising campaigns. Bold numbers were significant.

С	Campaigns Reaching Goal Amount (Successful Campaigns)							
	Univariable Analysis			Multivariable Analysis				
Characteristic	OR	95% CI	<i>p</i> -Value	OR	95% CI	<i>p</i> -Value		
Cancer								
Bladder	Ref.	Ref.		Ref.	Ref.			
Kidney	1.28	0.92–1.78	0.144	1.37	0.88-2.15	0.161		

Campaigns Reaching Goal Amount (Successful Campaigns)							
	Univariable Analysis			Multivariable Analysis			
Characteristic —	OR	95% CI	<i>p</i> -Value	OR	95% CI	<i>p</i> -Value	
Prostate	1.23	0.84–1.78	0.281	1.41	0.84–2.34	0.189	
Testicular	2.05	1.51-2.80	<0.001	2.03	1.34–3.11	<0.001	
Description (per 100 words)	0.96	0.92–1.01	0.010	-			
Shares (per 100)	1.02	1.01-1.03	0.003	1.03	1.01-1.05	<0.001	
Updates	1.01	1.00-1.01	0.254	-			
Days running (per 100)	1.02	0.99–1.04	0.167	-			
Religious references	0.73	0.57–0.92	0.007	0.79	0.58–1.06	0.118	
Treatment							
Conventional	Ref	Ref.		Ref.			
Alternative	0.43	0.17–0.89	0.022	0.51	0.20–1.13	0.099	
Both	0.61	0.29–1.16	0.142	0.76	0.35–1.47	0.431	
Children mentions	0.69	0.55–0.87	0.002	0.95	0.68–1.34	0.787	
Family status	0.75	0.59–0.97	0.028	0.78	0.54–1.12	0.175	
Job status	1.11	0.89–1.39	0.366	-			
Un-/underinsurance	0.70	0.53-0.90	0.006	0.83	0.61–1.14	0.251	
Provided data on cancer advancement	0.78	0.62-0.98	0.032	0.75	0.55-1.02	0.067	
Nonlocalized cancer	1.25	0.81-2.02	0.317	-			
Provided data on cancer histology	0.82	0.60-1.11	0.195	-			

Table 3. Cont.

Campaigns Reaching Goal Amount (Higest Quartile; >11,310\$) **Univariable Analysis Multivariable Analysis** Characteristic OR 95% CI *p*-Value OR 95% CI p-Value Cancer Bladder Ref. Ref. 1.46-2.54 1.92 < 0.001 1.28 0.80 - 2.070.294 Kidney 1.841.36-2.51 < 0.001 0.96 0.871 Prostate 0.56-1.63 Testicular 1.45 1.10-1.93 0.009 0.98 0.62 - 1.570.948 1.141.10-1.18 1.080.004 Description (per 100 words) < 0.001 1.02 - 1.14Shares (per 100) 1.13 1.11-1.15 < 0.001 1.13 1.10-1.16 < 0.001 1.000.823 Updates 1.03 1.02 - 1.04< 0.001 0.98-1.02 1.04 1.01 0.595 Days running (per 100) 1.02-1.06 < 0.001 0.98 - 1.04**Religious** references 1.02 0.84 - 1.250.82 -Treatment Conventional Ref. Ref. Alternative 2.04 1.27-3.23 0.005 0.003 2.56 1.33-4.99 2.91 1.86-4.55 Both < 0.001 2.151.22-3.79 0.009 Children mentions 1.13 0.92-1.37 0.237 -1.17-1.91 Family status 1.49 0.001 1.36 0.92-2.04 0.119

Model AUC 0.628

	Univariable Analysis			Multivariable Analysis		
Characteristic	OR	95% CI	<i>p</i> -Value	OR	95% CI	<i>p</i> -Value
Job status	1.07	0.88–1.30	0.512	-		
Un-/underinsurance	0.90	0.72–1.11	0.332	-		
Nonlocalized disease	2.40	1.57-3.69	<0.001	2.37	1.38-4.06	0.001
Provided data on cancer histology	1.13	0.88-1.45	0.342	-		
					Model AUC: 0.76	54

Table 3. Cont.

Abbreviations: CI: Confidence Interval; OR: Odds Ratio; Ref.: Reference.

#### 4. Discussion

In this study, we evaluated the current landscape of online crowdfunding for urologic cancer care using an automated approach to evaluate campaigns on GoFundMe.com. With growing recognition of the financial toxicities encountered during cancer diagnosis and treatment, particularly in the US healthcare system, this study highlighted the emergence of novel strategies enabled through enhanced social connectivity. There were several key findings of our study. First, while there were significant differences between campaigns directed at different urologic cancer types, testicular cancer campaigns were most likely to be successful. Second, campaigns fundraising for CAM, compared to conventional treatment, had higher fundraising totals and collected more per donor. Third, the number of social media shares was an independent predictor of the highest fundraising and campaign success.

These findings built on the work of other publications that have examined crowdfunding in urology [12,16,17]. For example, Di Carlo et al. analyzed 119 urology campaigns from Canada and found that urologic oncology campaigns fundraised more than campaigns raising for urologic benign conditions [12]. Notably, nine campaigns fundraising for testicular diseases were evaluated (all for benign conditions; none for testicular cancer) and these had the highest amount collected, similarly to our findings. Moreover, in another study, campaigns for prostate cancer were shown to collect significantly less than those for breast cancer [16]. Thomas et al. evaluated 486 GoFundMe® kidney campaigns and found that among 486 kidney cancer campaigns, only 8% were successful; the median goal was \$10,000, the median amount raised was \$1450 and the median number of donors was 17 [17]. We identified considerable heterogeneity in the amount of funding requested and raised by cancer type. Campaigns for testicular cancer were the most successful in terms of dollar amount raised, a finding that may reflect the effect of the younger age and broader social networks of these patients. Indeed, younger patients with cancer face greater financial toxicity due to comparatively fewer savings, higher rates of uninsurance and potential impacts on family members and dependents [11,18].

We also found that a greater number of social media shares were associated with measures of a campaign's success. These findings underscored the extent to which greater dissemination of campaigns may be an important component of successful fundraising. Our results expanded upon findings from previous studies examining the role of social media shares in online medical crowdfunding. For example, in a study of Fong et al., social media shares were correlated with amount raised [19]. Through analysis of 1100 GoFundMe campaigns directed at gender-affirming surgery, Akiki et al., determined that social media shares were associated with highest fundraising totals [20]. These results were also in agreement with an expanding body of work that has shown the role of social media in the promotion of other aspects of urologic care delivery, including the dissemination of novel research [21].

Lastly, we found that a large proportion of campaigns included fundraising for CAM treatments. Although there has been expanding interest in the use of these approaches [2], less has been known about the role of crowdfunding, given that they are frequently not covered by insurance. We further uncovered that campaigns directed at CAM treatments

were more successful by dollar amount, a finding that could reflect an awareness of greater unmet financial needs or greater public enthusiasm for these treatments. These findings unmasked the rise in the usage of CAM among patients with urologic cancers, particularly as their use as stand-alone therapy has been associated with worse cancer outcomes [22]. Finally, limitations of this study included the cross-sectional design and an emphasis on campaigns originating in the United States. Other limitations included disbalance of the dependent variable and lack of data on fundraisers' age. Future work could examine globally-directed crowdfunding campaigns.

### 5. Conclusions

To conclude, in this study, using a new novel web-based methodology analysis, we identified and characterized patients' reported financial needs for urologic cancer care. Notably, while the majority of campaigns gathered money for medical bills, nearly two-thirds aimed at collecting funds for daily living costs, which were main or additional goals. Furthermore, our findings indicated a diverse range of online crowdfunding campaigns, their outcomes and identifiable factors associated with campaigns' success. We showed that, while there were significant differences across campaigns fundraising for urologic cancers, testicular cancer initiatives were the most likely to succeed. Additionally, campaigns soliciting money for CAM had greater fundraising totals and raised more than efforts seeking money for conventional therapy. Finally, the number of social media shares was associated with successful campaign financing. Future research could examine crowdfunding efforts on a global basis.

Author Contributions: Conceptualization, P.R., S.F.S. and M.S.L.; methodology, P.R., P.H. and M.S.L.; software, P.H., H.M.; formal analysis, P.R., P.H. and D.D.; investigation: P.R., J.W., J.K., I.P. and O.L.-W.; data curation, J.W., J.K., I.P. and O.L.-W.; writing—original draft preparation: P.R., W.K., B.M. and B.P.; writing—review and editing, A.P., G.P., M.M., B.N.B., S.F.S. and M.S.L.; visualization, H.M.; supervision, B.P., S.F.S. and M.S.L.; project administration, P.R. and M.S.L.; All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by an EUSP Scholarship from the European Association of Urology to Pawel Rajwa. The sponsor played no direct role in the study.

**Institutional Review Board Statement:** Ethical review and approval were waived for this study, by the Yale University Institutional Review Board (IRB) which deemed it as nonhuman subjects' research.

Informed Consent Statement: Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

- Cohen, A.J.; Brody, H.; Patino, G.; Ndoye, M.; Liaw, A.; Butler, C.; Breyer, B.N. Use of an Online Crowdfunding Platform for Unmet Financial Obligations in Cancer Care. *JAMA Intern. Med.* 2019, 179, 1717–1720. [CrossRef] [PubMed]
- Song, S.; Cohen, A.J.; Lui, H.; Mmonu, N.A.; Brody, H.; Patino, G.; Liaw, A.; Butler, C.; Fergus, K.B.; Mena, J.; et al. Use of GoFundMe®to crowdfund complementary and alternative medicine treatments for cancer. J. Cancer Res. Clin. Oncol. 2020, 146, 1857–1865. [CrossRef] [PubMed]
- 3. Zenone, M.; Snyder, J.; Caulfield, T. Crowdfunding Cannabidiol (CBD) for Cancer: Hype and Misinformation on GoFundMe. *Am. J. Public Health* **2020**, *110*, S294–S299. [CrossRef] [PubMed]
- 4. Rajwa, P.; Hopen, P.; Mu, L.; Paradysz, A.; Wojnarowicz, J.; Gross, C.P.; Leapman, M.S. Online Crowdfunding Response to Coronavirus Disease 2019. *J. Gen. Intern. Med.* 2020, *35*, 2482–2484. [CrossRef]
- 5. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [CrossRef]
- 6. Imber, B.S.; Varghese, M.; Ehdaie, B.; Gorovets, D. Financial toxicity associated with treatment of localized prostate cancer. *Nat. Rev. Urol.* **2019**, 17, 28–40. [CrossRef]
- Casilla-Lennon, M.M.; Choi, S.K.; Deal, A.M.; Bensen, J.T.; Narang, G.; Filippou, P.; McCormick, B.; Pruthi, R.; Wallen, E.; Tan, H.-J.; et al. Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life. J. Urol. 2018, 199, 1166–1173. [CrossRef]

- 8. Ramsey, S.D.; Bansal, A.; Fedorenko, C.R.; Blough, D.K.; Overstreet, K.A.; Shankaran, V.; Newcomb, P. Financial Insolvency as a Risk Factor for Early Mortality Among Patients with Cancer. *J. Clin. Oncol.* **2016**, *34*, 980–986. [CrossRef]
- 9. Niedzwiedz, C.L.; Knifton, L.; Robb, K.A.; Katikireddi, S.V.; Smith, D.J. Depression and anxiety among people living with and beyond cancer: A growing clinical and research priority. *BMC Cancer* 2019, *19*, 943. [CrossRef]
- 10. Park, J.; Look, K.A. Health Care Expenditure Burden of Cancer Care in the United States. *Inquiry* 2019, *56*, 46958019880696. [CrossRef]
- Holler, J.T.; Hakam, N.; Nabavizadeh, B.; Sadighian, M.J.; Shibley, W.P.; Li, K.D.; Weiser, L.; Rios, N.; Enriquez, A.; Leapman, M.S.; et al. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urol. Pract. 2022, 9, 56–63. [CrossRef]
- 12. Di Carlo, A.; Leveridge, M.; McGregor, T.B. Crowdfunding in urology: Canadian perspective. *Can. Urol. Assoc. J.* **2020**, *15*, E139–E143. [CrossRef]
- Arnastauskaitė, J.; Ruzgas, T.; Bražėnas, M. An Exhaustive Power Comparison of Normality Tests. *Mathematics* 2021, 9, 788. [CrossRef]
- 14. Balakrishnan, N.; Brito, M.R.; Quiroz, A.J. On the goodness-of-fit procedure for normality based on the empirical characteristic function for ranked set sampling data. *Metrika* **2013**, *76*, 161–177. [CrossRef]
- 15. King, G.; Zeng, L. Logistic Regression in Rare Events Data. Political Anal. 2001, 9, 137–163. [CrossRef]
- 16. Loeb, S.; Taneja, S.; Walter, D.; Zweifach, S.; Byrne, N. Crowdfunding for prostate cancer and breast cancer. *Br. J. Urol.* 2018, 122, 723–725. [CrossRef]
- Thomas, H.S.; Lee, A.W.; Nabavizadeh, B.; Namiri, N.K.; Hakam, N.; Martin-Tuite, P.; Rios, N.; Enriquez, A.; Mmonu, N.A.; Cohen, A.J.; et al. Characterizing online crowdfunding campaigns for patients with kidney cancer. *Cancer Med.* 2021, 10, 4564–4574. [CrossRef]
- Kaddas, H.K.; Pannier, S.T.; Mann, K.; Waters, A.R.; Salmon, S.; Tsukamoto, T.; Warner, E.L.; Fowler, B.; Lewis, M.A.; Fair, D.B.; et al. Age-Related Differences in Financial Toxicity and Unmet Resource Needs Among Adolescent and Young Adult Cancer Patients. J. Adolesc. Young Adult Oncol. 2020, 9, 105–110. [CrossRef]
- 19. Fong, A.; Jain, M.; Sacks, W.; Ho, A.; Chen, Y. Crowdfunding Campaigns and Thyroid Surgery: Who, What, Where, and How Much? *J. Surg. Res.* **2020**, 253, 63–68. [CrossRef]
- 20. Akiki, R.K.; Borrelli, M.R.; Kwan, D. Online Crowdfunding Enables Patients' Access to Gender-Affirming Surgery. *Transgender Health* **2021**, *6*, 240–243. [CrossRef]
- Nolte, A.C.; Nguyen, K.A.; Perecman, A.; Katz, M.S.; Kenney, P.A.; Cooperberg, M.R.; Gross, C.P.; Leapman, M.S. Association Between Twitter Reception at a National Urology Conference and Future Publication Status. *Eur. Urol. Focus* 2021, 7, 214–220. [CrossRef] [PubMed]
- Johnson, S.B.; Park, H.S.; Gross, C.P.; Yu, J. Use of Alternative Medicine for Cancer and Its Impact on Survival. J. Natl. Cancer Inst. 2018, 110, 121–124. [CrossRef] [PubMed]